<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2121">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391179</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00179783</org_study_id>
    <nct_id>NCT04391179</nct_id>
  </id_info>
  <brief_title>Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19</brief_title>
  <acronym>DICER</acronym>
  <official_title>Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most severe manifestations of COVID-19 include respiratory failure, coagulation problems,
      and death. Inflammation and blood clotting are believed to play an important role in these
      manifestations. Research in humans has shown that dipyridamole can reduce blood clotting.
      This research study is being conducted to learn whether 14 days of treatment with
      dipyridamole will reduce excessive blood clotting in COVID-19.

      This study will enroll participants with confirmed coronavirus (SARS-CoV)-2 infection that
      are admitted. Eligible participants will be randomized to receive dipyridamole or placebo for
      14 days in the hospital. In addition, data will be collected from the medical record, and
      there will also be blood draws during the hospitalization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in D-dimer</measure>
    <time_frame>baseline, up to approximately 28 days after last study drug administration</time_frame>
    <description>Increase in plasma D-dimer level compared with baseline at enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global composite rank score</measure>
    <time_frame>up to approximately 28 days after last study drug administration</time_frame>
    <description>Global composite rank score of death, mechanical ventilation, oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2), and World Health Organization (WHO) Ordinal score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>COVID</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Covid-19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Dipyridamole 100 Milligram(mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 milligrams (mg) by mouth (PO) four times a day (QID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given by mouth four times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipyridamole 100 Milligram(mg)</intervention_name>
    <description>Drug will be given for 14 days while in the hospital.</description>
    <arm_group_label>Dipyridamole 100 Milligram(mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo will be given for 14 days while in the hospital.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent prior to performing study procedures
             unless they have a legally authorized representative (LAR)

          -  Confirmed coronavirus (SARS-CoV-2) infection, enrolled ≤ 72 hours of hospital
             admission or of COVID-19 confirmation

          -  Currently hospitalized or anticipated hospitalization requiring supplemental oxygen ≤
             6 liters per minute (LPM) by nasal cannula

        Exclusion Criteria:

          -  In the opinion of at least two investigators, unlikely to survive for &gt;48 hours from
             screening

          -  Concurrent enrollment in a clinical trial with a cytokine inhibitor (targeting
             interleukin-6 (IL-6), Interleukin-6 Receptor (IL-6R), IL-1, or Janus kinase). Use of
             remdesivir is permitted.

          -  Currently on invasive mechanical ventilation.

          -  Hypotension defined as systolic blood pressure &lt; 90 mmHg on two sequential readings at
             least 4 hours apart

          -  Pregnant or breastfeeding

          -  Concurrent dual antithrombotic therapy (aspirin or P2Y12 inhibitor plus
             anticoagulation to treat deep venous thrombosis or pulmonary embolism (single
             antiplatelet or anticoagulant agent at prophylaxis or therapeutic dose is permitted)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5
             times upper limit of normal, hemoglobin &lt; 8 grams per deciliter (g/dL), or platelets
             &lt;50,000 per cubic millimeter (mm3)

          -  History of recent major bleeding, defined in accordance with the criteria of the
             International Society on Thrombosis and Hemostasis (ISTH).

          -  Any physical examination findings and/or history of any illness that, in the opinion
             of the study investigator, might confound the results of the study or pose an
             additional risk to the patient by their participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Knight, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neha Shah</last_name>
    <phone>734-232-4606</phone>
    <email>neshah@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Knight, MD</last_name>
    <phone>734-615-1880</phone>
    <email>jsknight@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>North Shore UniversityHealth</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Frech</last_name>
      <phone>847-570-4046</phone>
      <email>RFrech@northshore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neha Shah</last_name>
      <phone>734-232-4606</phone>
      <email>neshah@umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Jason Scott Knight</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Oxygen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

